131875-08-6
中文名稱
來沙骨化醇
英文名稱
Lexacalcitol
CAS
131875-08-6
分子式
C29 H48 O4
分子量
460.69
MOL 文件
131875-08-6.mol
更新日期
2025/01/09 09:24:41
131875-08-6 結(jié)構(gòu)式
基本信息
中文別名
來沙骨化醇 英文別名
KH 106KH 1060
Lexacalcitol
Lenosacalcitol
Lexacalcideferol
(1S*,3R*,5Z),7aalpha))-(5Z,7E,20R)-20-((4-Ethyl-4-hydroxyhexyl)oxy)-9,10-secopregna-5,7,10(19)-triene-1alpha,3beta-diol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-[(4-ethyl-4-hydroxyhexyl)oxy]ethyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)-
(1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
所屬類別
生物化工：激動(dòng)劑抑制劑物理化學(xué)性質(zhì)
沸點(diǎn)600.3±55.0 °C(Predicted)
密度1.07±0.1 g/cm3(Predicted)
儲(chǔ)存條件-20°C, protect from light, stored under nitrogen,unstable in solution, ready to use.
溶解度DMSO
酸度系數(shù)(pKa)14.43±0.40(Predicted)
形態(tài)粉末
顏色White to off-white
來沙骨化醇價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-32340 | 來沙骨化醇 Lexacalcitol | 131875-08-6 | 1mg | 2560元 |
| 2024/08/19 | HY-32340 | 來沙骨化醇 Lexacalcitol | 131875-08-6 | 5mg | 6400元 |
| 2023/10/26 | HY-32340 | 來沙骨化醇 Lexacalcitol | 131875-08-6 | 10mg | 12500元 |
常見問題列表
生物活性
Lexacalcitol (KH1060) 是一種維生素 D 類似物，是細(xì)胞生長(zhǎng)和免疫反應(yīng)的有效調(diào)節(jié)劑。Lexacalcitol 可用于移植排斥反應(yīng)、銀屑病、癌癥和自身免疫性疾病的研究。體外研究
Lexacalcitol inhibits cell proliferation by 50% at 10
-12
M (14,000 times more active than la,25(OH)
2
D
3
) in human histiocytic lymphoma cell line U 937.
Lexacalcitol inhibits interleukin-1-induced mouse thymocyte proliferation by 50% at 3×10
-16
M , allogeneic stimulation of mouse spleen lymphocytes at 5×10
-15
M.
體內(nèi)研究
Lexacalcitol (0.5 mg/kg/2 days; i.p.) in combination with cyclosporin A (CyA) can prevent autoimmune destruction of syngeneic islet grafts in spontaneously diabetic NOD recipients.
| Animal Model: | Male and female spontaneously diabetic NOD mice |
| Dosage: | 0.5 mg/kg/2 days |
| Administration: | Intraperitoneal injection |
| Result: | Single treatment with KH1060 or CyA did not result in statistically significant suppression of early graft failure, while the combination of KH1060 and CyA can prevent early graft failure and delay graft rejection of xenogeneic islets in spontaneously diabetic NOD mice. |